<?xml version="1.0" encoding="UTF-8"?>
<p>Dual CDKs/GSK-3β inhibition is a promising therapeutic approach to confront uncontrolled cancer cell proliferation
 <xref rid="CIT0035" ref-type="bibr">
  <sup>35</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0036" ref-type="bibr">
  <sup>36</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0051" ref-type="bibr">
  <sup>51</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0059" ref-type="bibr">
  <sup>59–66</sup>
 </xref>. In particular, CDK2 and GSK-3β share a high homologous sequence (33% amino acid identity) and are used as examples for the homological CMGC protein kinase family
 <xref rid="CIT0059" ref-type="bibr">
  <sup>59</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0064" ref-type="bibr">
  <sup>64</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0067" ref-type="bibr">
  <sup>67–75</sup>
 </xref>. Therefore, designing dual CDK2/GSK-3β inhibitors as anticancer agents is an amenable and attractive strategy
 <xref rid="CIT0065" ref-type="bibr">
  <sup>65–66</sup>
 </xref>.
</p>
